W
bioLLM/wiki

AI-Curated Biomedical Knowledge Base

Live
Back to List ViewGraph View

ceftazidime-avibactam

Overview

Ceftazidime-avibactam is a combination antibacterial therapy consisting of the third-generation cephalosporin ceftazidime and the non-β-lactam β-lactamase inhibitor avibactam. It is designed to restore or enhance ceftazidime activity against many Gram-negative bacteria that produce β-lactamases, including some carbapenemase-producing Enterobacterales. Clinically, it is used for serious multidrug-resistant infections in settings where standard β-lactam therapy may be ineffective.

Its medical significance lies in its role as a targeted option for difficult-to-treat Gram-negative infections, particularly those caused by organisms such as Klebsiella pneumoniae, Enterobacter cloacae complex, and Pseudomonas aeruginosa. Because resistance can emerge through β-lactamase evolution, porin changes, efflux upregulation, or acquisition of metallo-β-lactamases such as NDM, ceftazidime-avibactam is often discussed alongside aztreonam, aztreonam-avibactam, cefiderocol, meropenem-vaborbactam, and imipenem/relebactam in the context of contemporary antimicrobial stewardship and resistance management.

Recent Publications Summary

Recent real-world studies have continued to evaluate ceftazidime-avibactam as a treatment for difficult gram-negative infections, particularly carbapenem-resistant Enterobacterales (CRE) bacteremia and other multidrug-resistant (MDR) infections. In a retrospective cohort from Korea, adults with CRE bacteremia treated between January 2022 and July 2024 were compared according to receipt of ceftazidime-avibactam within 5 days of blood culture versus best available therapy; among 194 patients, the 14-day mortality rate was reported to be significantly lower in the ceftazidime-avibactam group 42411238Jul. A separate multicenter retrospective study across 22 U.S. medical centers (2019-2025) examined 613 adults with MDR gram-negative infections treated with ceftazidime-avibactam for at least 72 hours, with pneumonia the most common source and Pseudomonas aeruginosa and CRE the most frequent pathogens; composite clinical success occurred in 64.8%, and early initiation within 48 hours was assessed as a potential predictor of outcome 42138697May.

Other publications focused on resistance emergence and comparative effectiveness. In paired baseline and post-exposure Pseudomonas aeruginosa isolates from patients treated with ceftazidime-avibactam, treatment-emergent resistance was linked to ampC and OXA β-lactamase substitutions or regulatory mutations associated with hyperproduction of AmpC and MexAB-OprM efflux pumps; cross-resistance was common with ceftolozane-tazobactam, less common with imipenem-relebactam and cefepime-zidebactam, and lowest with cefiderocol 41940815Apr. In a propensity-score-weighted cohort of 73 patients with KPC-producing Enterobacterales infections, 30-day mortality was similar between ceftazidime-avibactam and meropenem-vaborbactam, but resistance emerged more often in the ceftazidime-avibactam group, with putative mechanisms including porin mutations in Klebsiella pneumoniae and R2 loop structural changes in AmpC in Enterobacter cloacae complex 41870149Mar.

Ceftazidime-avibactam was also used as part of an in vitro surrogate regimen in studies of Stenotrophomonas maltophilia complex. In comparative testing of aztreonam-avibactam versus aztreonam plus ceftazidime-avibactam, both regimens showed similar MIC distributions and bactericidal activity against most isolates, with no meaningful difference in time-kill performance under the tested conditions 41874381Mar.

⚠️ Content is generated using Large Language Models (LLMs) and may contain errors or hallucinations. Experts periodically review it to verify accuracy and maintain database integrity.